Avotermin for scar improvement following scar revision surgery: A randomized, double-blind, within-patient, placebo-controlled, phase II clinical trial

Plastic and Reconstructive Surgery

Volumn 128, Issue 1, 2011, Pages 163-172

  So, Karen ^a,b,c,d,e,f   McGrouther, Duncan A ^a,b,c,d,e,f   Bush, James A ^a,b,c,d,e,f   Durani, Piyush ^a,b,c,d,e,f   Taylor, Lisa ^a,b,c,d,e,f   Skotny, Gaynor ^a,b,c,d,e,f   Mason, Tracey ^a,b,c,d,e,f   Metcalfe, Anthony ^a,b,c,d,e,f   Okane, Sharon ^a,b,c,d,e,f   Ferguson, Mark W J ^a,b,c,d,e,f  

^a Renovo   (United Kingdom)

^b Faculty of Medical and Human Sciences ^*

^c Faculty of Medical and Human Sciences   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e LEICESTER ROYAL INFIRMARY   (United Kingdom)

^f ULSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TGFB3 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA3;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REOPERATION; SCAR;

ADULT; AGED; CICATRIX; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; REOPERATION; TRANSFORMING GROWTH FACTOR BETA3; YOUNG ADULT;

EID: 79959918155     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/PRS.0b013e318217429b     Document Type: Article

References (13)

1. Young VL, Hutchison J. Insights into patient and clinician concerns about scar appearance: Semiquantitative structured surveys. Plast Reconstr Surg. 2009;124:256-265.
2. American Society of Plastic Surgeons. 2010 Report of the 2009 Statistics National Clearinghouse of Plastic Surgery Statistics. Available at: http://www.plasticsurgery.org/Documents/Media/statistics/2009-US- cosmeticreconstructive plasticsurgeryminimally-invasive-statistics.pdf. Accessed December 10, 2010.
3. Bayat A, McGrouther DA, Ferguson MW. Skin scarring. BMJ. 2003;326:88-92. (Pubitemid 36092292)
4. Ferguson MW, O'Kane S. Scar-free healing: From embryonic mechanisms to adult therapeutic intervention. Philos Trans R Soc Lond B Biol Sci. 2004;359:839-850. (Pubitemid 38673751)
5. O'Kane S, Ferguson MW. Transforming growth factor beta s and wound healing. Int J Biochem Cell Biol. 1997;29:63-78. (Pubitemid 27096420)
6. Occleston NL, Laverty HG, O'Kane S, Ferguson MW. Prevention and reduction of scarring in the skin by transforming growth factor beta 3 (TGFbeta3): From laboratory discovery to clinical pharmaceutical. J Biomater Sci Polym Ed. 2008;19: 1047-1063. (Pubitemid 351957390)
7. Occleston NL, O'Kane S, Goldspink N, Ferguson MW. New therapeutics for the prevention and reduction of scarring. Drug Discov Today 2008;13:973-981.
8. Occleston NL, Metcalfe AD, Boanas A, et al. Therapeutic improvement of scarring: Mechanisms of scarless and scarforming healing and approaches to the discovery of new treatments. Dermatol Res Pract. 2010;405262:pii.
9. Shah M, Foreman DM, Ferguson MW. Neutralisation of TGFbeta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. J Cell Sci. 1995; 108:985-1002.
10. Ferguson MW, Duncan J, Bond J, et al. Prophylactic administration of avotermin for improvement of skin scarring: Three double-blind, placebo-controlled, phase I/II studies. Lancet 2009;373:1264-1274.
11. Duncan JA, Bond JS, Mason T, et al. Visual analogue scale scoring and ranking: A suitable and sensitive method for assessing scar quality? Plast Reconstr Surg. 2006;118:909-918. (Pubitemid 44412923)
12. Beausang E, Floyd H, Dunn KW, Orton CI, Ferguson MW. A new quantitative scale for clinical scar assessment. Plast Reconstr Surg. 1998;102:1954-1961. (Pubitemid 28518519)
13. Bush J, Duncan JA, Bond JS, et al. Scar-improving efficacy of avotermin administered into the wound margins of skin incisions as evaluated by a randomized, double-blind, placebocontrolled, phase II clinical trial. Plast Reconstr Surg. 2010; 126:1604-1615.